Edoxaban Tablets

DRUG2 trials

Sponsors

Imperial College London, Insel Gruppe AG, University Hospital Bern

Conditions

Atrial FibrillationCOVID-19Intracerebral HemorrhageSARS-CoV Infection

Phase 3

PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation

CompletedNCT03996772

Imperial College LondonAtrial Fibrillation, Intracerebral Hemorrhage

Start: 2019-06-03End: 2024-05-31Updated: 2025-01-13

CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19

TerminatedNCT04516941

Insel Gruppe AG, University Hospital BernCOVID-19, SARS-CoV Infection

Start: 2021-01-21End: 2022-08-31Updated: 2022-09-08

Related Papers

Neuroimaging Markers Associated With Recurrent Stroke in Intracerebral Hemorrhage and Atrial Fibrillation: Secondary Analysis of PRESTIGE-AF.

2025-11-06

Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.

2025-02-2616 citations

Edoxaban and/or colchicine in outpatients with COVID-19: rationale and design of the CONVINCE trial

Journal of Cardiovascular Medicine2023-11-032 citations

Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

2022-06-3043 citations

77 Preventing stroke in patients with atrial fibrillation and intracerebral haemorrhage: a qualitative study of physicians’ decision-making

2022-06-01

Abstract WP83: The Challenges Of Stroke Prevention Following Intracerebral Haemorrhage; A Qualitative Study Exploring Physicians’ Decision Making.

Stroke2022-02-01